CIK 0002044725
- Emerging growth company
Evommune, Inc.
Sign in to watch- Ticker
- EVMN
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 850742575
- Phone
- +1 650-223-7745
- Business address
- 1891 PAGE MILL RD, PALO ALTO, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-13 | Patel Jeegar Pravinkumar Chief Scientific Officer | Returned to the company · Stock Option (Right to buy) | −179,619 | 0 | ||
| 2026-11-13 | Patel Jeegar Pravinkumar Chief Scientific Officer | Grant or award · Stock Option (Right to buy) | +179,619 | 179,619 | ||
| 2026-11-13 | Patel Jeegar Pravinkumar Chief Scientific Officer | Returned to the company · Stock Option (Right to buy) | −69,315 | 0 | ||
| 2026-11-13 | Patel Jeegar Pravinkumar Chief Scientific Officer | Grant or award · Stock Option (Right to buy) | +69,315 | 69,315 | ||
| 2026-11-13 | Drew Janice Suzann Chief of Dev. Operations | Returned to the company · Stock Option (Right to buy) | −231,274 | 0 | ||
| 2026-11-13 | Drew Janice Suzann Chief of Dev. Operations | Grant or award · Stock Option (Right to buy) | +231,274 | 231,274 | ||
| 2026-11-13 | Drew Janice Suzann Chief of Dev. Operations | Returned to the company · Stock Option (Right to buy) | −73,892 | 0 | ||
| 2026-11-13 | Drew Janice Suzann Chief of Dev. Operations | Grant or award · Stock Option (Right to buy) | +73,892 | 73,892 | ||
| 2026-11-13 | Carver Kyle Chief Financial Officer | Returned to the company · Stock Option (Right to buy) | −279,408 | 0 | ||
| 2026-11-13 | Carver Kyle Chief Financial Officer | Grant or award · Stock Option (Right to buy) | +279,408 | 279,408 | ||
| 2026-11-13 | Carver Kyle Chief Financial Officer | Returned to the company · Stock Option (Right to buy) | −98,946 | 0 | ||
| 2026-11-13 | Carver Kyle Chief Financial Officer | Grant or award · Stock Option (Right to buy) | +98,946 | 98,946 | ||
| 2026-11-13 | Moss Gregory S. Chief Business & Legal Officer | Returned to the company · Stock Option (Right to buy) | −293,496 | 0 | ||
| 2026-11-13 | Moss Gregory S. Chief Business & Legal Officer | Grant or award · Stock Option (Right to buy) | +293,496 | 293,496 | ||
| 2026-11-13 | Moss Gregory S. Chief Business & Legal Officer | Returned to the company · Stock Option (Right to buy) | −115,279 | 0 | ||
| 2026-11-13 | Moss Gregory S. Chief Business & Legal Officer | Grant or award · Stock Option (Right to buy) | +115,279 | 115,279 | ||
| 2026-11-13 | Bauer Eugene Chief Medical Officer | Returned to the company · Stock Option (Right to buy) | −100,000 | 0 | ||
| 2026-11-13 | Bauer Eugene Chief Medical Officer | Grant or award · Stock Option (Right to buy) | +100,000 | 100,000 | ||
| 2026-11-13 | Bauer Eugene Chief Medical Officer | Returned to the company · Stock Option (Right to buy) | −51,117 | 0 | ||
| 2026-11-13 | Bauer Eugene Chief Medical Officer | Grant or award · Stock Option (Right to buy) | +51,117 | 51,117 |
Page 1 of 8 · 145 trades